Treatment Action Group Challenges OMB Plan to Politicize Research Grants

The proposed overhaul would grant political officials the power to approve, deny, or cancel research awards based on administrative priorities, effectively bypassing congressional spending authority. TAG argues this move signals a dangerous expansion of executive overreach, citing a history of problematic grant terminations that have already disrupted CDC disease surveillance and stalled international HIV vaccine trials.

Beyond administrative concerns, the organization highlights the specific impact on vulnerable populations. New restrictions on international collaboration and provisions targeting research into gender and health disparities would severely hinder studies essential to treating HIV and hepatitis C in transgender communities and children worldwide. With nearly 500,000 public comments already logged, TAG is now demanding a 60-day extension to the review period, insisting that the rule be withdrawn entirely or struck down by the courts.